FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890108795> ?p ?o ?g. }

• W2890108795 abstract "5049 Background: A heterogeneous landscape of patients with metastatic castration-resistant prostate cancer (mCRPC) exists in current clinical practice. We investigated the prognostic value of CTC enumeration and dynamics, in the context of second-line endocrine therapies (i.e. abiraterone or enzalutamide). Methods: In a prospective, multicentre study blood samples were collected from patients with mCRPC at baseline (n = 147) and follow-up (n = 95/147(64.6%)). At baseline, patients were stratified in favourable ( < 5 CTCs/7.5mL) and unfavourable (≥5 CTCs/7.5mL) groups, whereas at follow-up, in those demonstrating a stable, in- or decreasing CTC count. PFS and OS were compared between groups. PSA changes at 10-12 weeks were evaluable in 83 patients. Results: Patients with ≥5 CTCs/7.5 mL (n = 59) at baseline had a shorter PFS (3.9 vs. 11.3 months, p< 0.0001) and OS (9.34 months vs. not reached, p< 0.0001). Patients demonstrating increasing CTCs (n = 21) on therapy had a shorter PFS (4.03 vs. 10.36 vs. 13.08 months, p < 0.0001) and OS (11.2 months vs. not reached, p < 0.0001), compared to patients with decreasing (n = 41) and stable (n = 33) CTCs, respectively. Multivariate Cox regression showed that the number of CTCs (HR (95%CI): 1.0054 (1.0006–1.010), p= 0.0260) and an increasing follow-up CTC count (HR (95%CI): 2.8987 (1.2856–6.536), p= 0.0103) were independent predictors of PFS. CTC increase was the sole independent predictor for OS (HR (95%CI): 7.3512 (1.7953–30.101), p= 0.0055). At 10-12 weeks, a PSA response of ≥30% and ≥50% was achieved in 46/83 (55.4%) and 33/83 (39.8%) patients, respectively, which was statistically different between chemo-naive or -pretreated patients (≥30%: p= 0.0395), patients with increasing, stable or decreasing CTC counts (≥30%: p= 0.0019; ≥50%: p= 0.0032), and patients with increasing or stable/decreasing CTC counts (≥30%: p= 0.0006; ≥50%: p= 0.0014). Conclusions: CTC levels are associated with PFS and OS in mCRPC patients, starting a new line of endocrine therapy. Follow-up CTC enumeration is associated with PSA response and its dynamics is an independent predictor of PFS and OS, thereby demonstrating the pharmacodynamic properties of CTCs." @default.
• W2890108795 created "2018-09-27" @default.
• W2890108795 creator A5000802010 @default.
• W2890108795 creator A5011210185 @default.
• W2890108795 creator A5014501814 @default.
• W2890108795 creator A5022173747 @default.
• W2890108795 creator A5027015803 @default.
• W2890108795 creator A5032321140 @default.
• W2890108795 creator A5043982080 @default.
• W2890108795 creator A5047006962 @default.
• W2890108795 creator A5058503850 @default.
• W2890108795 creator A5058731599 @default.
• W2890108795 creator A5058970752 @default.
• W2890108795 creator A5059965685 @default.
• W2890108795 creator A5066085340 @default.
• W2890108795 creator A5068362442 @default.
• W2890108795 creator A5078163245 @default.
• W2890108795 creator A5083566572 @default.
• W2890108795 creator A5085915218 @default.
• W2890108795 creator A5089057541 @default.
• W2890108795 creator A5089357269 @default.
• W2890108795 creator A5091141620 @default.
• W2890108795 date "2017-05-20" @default.
• W2890108795 modified "2023-09-27" @default.
• W2890108795 title "Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer." @default.
• W2890108795 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.5049" @default.
• W2890108795 hasPublicationYear "2017" @default.
• W2890108795 type Work @default.
• W2890108795 sameAs 2890108795 @default.
• W2890108795 citedByCount "0" @default.
• W2890108795 crossrefType "journal-article" @default.
• W2890108795 hasAuthorship W2890108795A5000802010 @default.
• W2890108795 hasAuthorship W2890108795A5011210185 @default.
• W2890108795 hasAuthorship W2890108795A5014501814 @default.
• W2890108795 hasAuthorship W2890108795A5022173747 @default.
• W2890108795 hasAuthorship W2890108795A5027015803 @default.
• W2890108795 hasAuthorship W2890108795A5032321140 @default.
• W2890108795 hasAuthorship W2890108795A5043982080 @default.
• W2890108795 hasAuthorship W2890108795A5047006962 @default.
• W2890108795 hasAuthorship W2890108795A5058503850 @default.
• W2890108795 hasAuthorship W2890108795A5058731599 @default.
• W2890108795 hasAuthorship W2890108795A5058970752 @default.
• W2890108795 hasAuthorship W2890108795A5059965685 @default.
• W2890108795 hasAuthorship W2890108795A5066085340 @default.
• W2890108795 hasAuthorship W2890108795A5068362442 @default.
• W2890108795 hasAuthorship W2890108795A5078163245 @default.
• W2890108795 hasAuthorship W2890108795A5083566572 @default.
• W2890108795 hasAuthorship W2890108795A5085915218 @default.
• W2890108795 hasAuthorship W2890108795A5089057541 @default.
• W2890108795 hasAuthorship W2890108795A5089357269 @default.
• W2890108795 hasAuthorship W2890108795A5091141620 @default.
• W2890108795 hasConcept C121608353 @default.
• W2890108795 hasConcept C126322002 @default.
• W2890108795 hasConcept C143998085 @default.
• W2890108795 hasConcept C2775832370 @default.
• W2890108795 hasConcept C2776421732 @default.
• W2890108795 hasConcept C2776551883 @default.
• W2890108795 hasConcept C2777899217 @default.
• W2890108795 hasConcept C2778971682 @default.
• W2890108795 hasConcept C2779256933 @default.
• W2890108795 hasConcept C2780192828 @default.
• W2890108795 hasConcept C2781190966 @default.
• W2890108795 hasConcept C3019894029 @default.
• W2890108795 hasConcept C502942594 @default.
• W2890108795 hasConcept C61367390 @default.
• W2890108795 hasConcept C71315377 @default.
• W2890108795 hasConcept C71924100 @default.
• W2890108795 hasConceptScore W2890108795C121608353 @default.
• W2890108795 hasConceptScore W2890108795C126322002 @default.
• W2890108795 hasConceptScore W2890108795C143998085 @default.
• W2890108795 hasConceptScore W2890108795C2775832370 @default.
• W2890108795 hasConceptScore W2890108795C2776421732 @default.
• W2890108795 hasConceptScore W2890108795C2776551883 @default.
• W2890108795 hasConceptScore W2890108795C2777899217 @default.
• W2890108795 hasConceptScore W2890108795C2778971682 @default.
• W2890108795 hasConceptScore W2890108795C2779256933 @default.
• W2890108795 hasConceptScore W2890108795C2780192828 @default.
• W2890108795 hasConceptScore W2890108795C2781190966 @default.
• W2890108795 hasConceptScore W2890108795C3019894029 @default.
• W2890108795 hasConceptScore W2890108795C502942594 @default.
• W2890108795 hasConceptScore W2890108795C61367390 @default.
• W2890108795 hasConceptScore W2890108795C71315377 @default.
• W2890108795 hasConceptScore W2890108795C71924100 @default.
• W2890108795 hasLocation W28901087951 @default.
• W2890108795 hasOpenAccess W2890108795 @default.
• W2890108795 hasPrimaryLocation W28901087951 @default.
• W2890108795 hasRelatedWork W2791065691 @default.
• W2890108795 isParatext "false" @default.
• W2890108795 isRetracted "false" @default.
• W2890108795 magId "2890108795" @default.
• W2890108795 workType "article" @default.